Home > News > Dabur Pharma eyes China & Japan entry
August 2nd, 2007
Dabur Pharma eyes China & Japan entry
Abstract:
Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened ‘Nanoxel'. At the moment, it sells the popular anti-cancer drug ‘Paclitaxel' on this platform. "We also want to export this portfolio of drugs in US, Europe and South-east Asian markets," said Mr Vij.
Source:
economictimes.indiatimes.com
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Acquisitions/Mergers/Splits
180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020
180 Degree Capital Corp.’s Portfolio Company, Synacor, Inc., Agrees to Merge with Qumu Corporation in All-Stock Transaction February 11th, 2020
Combination of Nanometrics and Rudolph Technologies to Create Onto Innovation October 16th, 2019
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||